Senti Biosciences (NASDAQ:SNTI) Price Target Raised to $12.00 at Chardan Capital

Senti Biosciences (NASDAQ:SNTI) had its target price raised by equities researchers at Chardan Capital from $11.00 to $12.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research firms have also commented on SNTI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.75.

Senti Biosciences Stock Up 8.0%

NASDAQ SNTI opened at $1.04 on Friday. The company has a fifty day moving average of $0.95 and a two-hundred day moving average of $1.22. The firm has a market capitalization of $32.39 million, a price-to-earnings ratio of -0.33 and a beta of 2.09. Senti Biosciences has a 52 week low of $0.77 and a 52 week high of $3.88.

Senti Biosciences (NASDAQ:SNTI) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.22. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Equities research analysts anticipate that Senti Biosciences will post -1.03 EPS for the current year.

Institutional Trading of Senti Biosciences

A number of large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences during the fourth quarter valued at $46,000. Jane Street Group LLC bought a new stake in shares of Senti Biosciences in the fourth quarter valued at about $40,000. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences in the third quarter valued at about $117,000. Armistice Capital LLC bought a new stake in shares of Senti Biosciences in the second quarter valued at about $1,883,000. Finally, Geode Capital Management LLC raised its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares in the last quarter. 25.70% of the stock is owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.